Veristat is an innovative full-service, science-focused clinical research organization (CRO) with over 20 years of experience in supporting clinical trials and regulatory submissions for pharmaceutical, biotechnology, and medical device companies. Veristat offers comprehensive clinical development services, including biostatistics, statistical programming, medical writing, clinical monitoring, project management and data management, for a single study or an entire clinical program, as well as preparation of integrated summary documents and submission-ready CDISC data for regulatory filings. Due to Veristat’s unwavering commitment to scientific integrity, client focus and exceptional performance, long-lasting client relationships are our hallmark.

HQSouthborough, US
Size (employees)181 (est)+6%
Veristat was founded in 1994 and is headquartered in Southborough, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Veristat Office Locations

Veristat has offices in San Bruno, Southborough, Cambridge, Montréal and in 1 other location
Southborough, US (HQ)
200 118 Turnpike Rd
Cambridge, US
1 Broadway
San Bruno, US
268 1001 Bayhill Dr
Montréal, CA
1030 1450 Rue City Councillors
Show all (5)
Report incorrect company information

Veristat Financials and Metrics

Summary Metrics

Founding Date

Report incorrect company information

Veristat Online and Social Media Presence

Embed Graph
Report incorrect company information

Veristat Blogs

When Veristat Walks – Cancer Runs

In 1964, a child’s chance of surviving the most common form of Leukemia was 3%.  Today it has increased to 91%!  

Veristat Strengthens Clinical Operations Capabilities with The Acquisition of Topstone Research

Expanding Its Clinical Operations and Biometrics Teams Dedicated to Emerging, Small and Mid-Sized Biopharma

What Pharma Companies Need to Know Before Designing an Adaptive Clinical Trial

By John Balser, PhD, President, Mark Chang, PhD, Senior Vice President, and Robin Bliss, PhD, Director The Food and Drug Administration (FDA) has started encouraging the use of adaptive designs for clinical studies. In essence, adaptive designs allow prospectively planned modifications…

Is Your Complex NDA/MAA Submission Missing One of These Key Elements?

By Martha Plaza, MBA; Amanda Truesdale, MA, MBA; and Kimberly Newton, MA. 

Veristat Congratulates Alnylam on the FDA Approval of ONPATTRO™

Continues Collaboration to Provide Regulatory Submission Support for Additional Patisiran Submissions   SOUTHBOROUGH, MA –  August 20, 2018 –   Veristat, a full service Clinical Research Organization (CRO), congratulates Alnylam on the recent FDA approval of ONPATTRO™ (patisiran), a …

Veristat Congratulates Agios on the FDA Approval of TIBSOVO®

 The First Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation   SOUTHBOROUGH, MA –  August 16, 2018 –   Veristat, a full service Clinical Research Organization (CRO), congratulates Agios on the recent FDA approval of TIBSOVO® (ivosi…
Show more

Veristat Company Life and Culture

Report incorrect company information